2Q21 earnings presentation

2Q21 select financial highlights Top line 2021 2Q19 Third party sales 2Q20 $1,198M $2,094M $1,863M 2Q21 sales of $2.1B, up +11% cc¹ vs. 2Q19, with growth across all five sales categories Alcon Market share gains coupled with strong market recovery in US Surgical outperformed the market, ATIOLs growing share Vision Care returned to growth on key products: Precision1, Pataday and Systane Core operating margin 2Q21 2020 Profitability 2019 (6.6%) 18.2% 16.6% Core operating margin up 160 bps vs. 2Q19 Operating leverage and reduced investments in COVID-impacted markets 70 bps positive impact from FX vs. 2Q20 10 bps negative impact from FX vs. 2Q19 2Q21 Core EPS 2Q19 1 Core diluted EPS 2020 ($0.21) $0.56 $0.47 2Q21 core diluted EPS of $0.56, up 9 cents or 19% vs. 2Q19 2020 was impacted by lower sales, unfavorable manufacturing absorption, provisions for expected credit losses due to COVID-19 and inventory provisions 1H21 Cash generation 1H19 Free cash flow 1H20 ($110M) $95M $320M 1H21 cash from operations of $542 million 1. Constant currency, core operating margin, core diluted EPS and free cash flow are non-IFRS measures. An explanation of non-IFRS measures can be found in the Appendix. Higher free cash flow vs. 1H19 driven by higher core operating income and lower separation spend, partially offset by increased inventory to support upcoming demand and new product launches 01 6

View entire presentation